IPHA - MCAP CO - Innate Pharma S.A.

Geopolitical fragmentation is hindering global testing of new drugs and the procurement of bio-resources, slowing their commercialization. Meanwhile, the French developer Innate Pharma S.A. (IPHA) is creating antibodies to stimulate immunity, maintaining its scientific priority through research investments. The asset's capitalization stands at 0.16. The price trend shown below complements data on stable growth and licensing revenues that support current R&D.

Innate Pharma S.A. (IPHA) is developing the unique ANKET platform, creating value through long-term licensing agreements with global pharmaceutical behemoths. The market value dynamics of all company shares reflect the market's real-time assessment of these intellectual assets. This metric is calculated as the product of the share price and the total number of shares, merging fundamental data with market sentiment. It is critical for investors to benchmark this indicator against the growth potential of the company's developments. The stability of the chart confirms the financial resilience of the business capital.